There is also evidence that TNF inhibitors can trigger or unmask myositis in predisposed individuals: several reports detail new-onset dermatomyositis occurring after 2–6 months of etanercept or adalimumab therapy for arthritis (32). The gene discussed is TNF; the disease is dermatomyositis.